MisraA, TandonN, EbrahimS, et al.: Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ, 2017; 357:j1420.
2.
MisraA, RamchandranA, JayawardenaR, et al.: Diabetes in South Asians. Diabet Med, 2014; 31:1153–1162.
3.
ChristensenDH, RungbyJ, ThomsenRW: Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014. Clin Epidemiol, 2016; 8:381–387.
4.
OuHT, ChangKC, LiuYM, WuJS: Recent trends in the use of antidiabetic medications from 2008 to 2013: a nation-wide population-based study from Taiwan. J Diabetes, 2017; 9:256–266.
5.
AIOCD: AWACS Pharma Data Platform. https://aiocdawacs.com/Default.aspx (accessed October19, 2017).
6.
PrinjaS, BahugunaP, TripathyJP, KumarR: Availability of medicines in public sector health facilities of two North Indian States. BMC Pharmacol Toxicol, 2015; 16:43.
7.
GwatidzoSD, Stewart WilliamsJ: Diabetes mellitus medication use and catastrophic healthcare expenditure among adults aged 50+ years in China and India: results from the WHO study on global AGEing and adult health (SAGE). BMC Geriatr, 2017; 17:14.
8.
ShrivastavaU, MisraA, GuptaR, ViswanathanV: Socioeconomic factors relating to diabetes and its management in India. J Diabetes, 2016; 8:12–23.
9.
Ramachandran A1, RamachandranS, SnehalathaC, et al.: Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care, 2007; 30:252–256.
10.
BeranD, EwenM, LaingR: Constraints and challenges in access to insulin: global perspective. Lancet Diabetes Endocrinol, 2016; 4:275–285.
11.
LipskaKJ, RossJS, Van HoutenHK, et al.: Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA, 2014; 311:2331–2333.
12.
1.5 Lakh Crore Spend on Diabetes in India Annually, and Rising by 30% per Year. Times of India, February9, 2016. http://www.pharmaion.com/news/310-1-5-lakh-crore-spend-on-diabetes-in-india-annually-and-rising-by-30-per-year.html (accessed October19, 2017).
13.
HorvathK, JeitlerK, BergholdA, et al.: Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2009:CD005613.
14.
MannucciE, MonamiM, MarchionniN: Short-acting insulin analogues vs regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract, 2008; 81:184–189.
15.
WaughN, CumminsE, RoyleP, et al.: Newer agents for glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess, 2010; 14:1–248.
16.
CameronCG, BennettHA: Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ, 2009; 180:400–407.
17.
BiY, LiX, YangD, et al.: Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy. Systemic review and meta-analyses. J Diabetes Investig, 2012; 3:283–293.
India Diabetes Management Algorithm Proposal Group: A proposed India-specific algorithm for management of type 2 diabetes. Diabetes Technol Ther, 2016; 18:346–350.
